Barrier Therapeutics Inc., of Princeton, N.J., appointed Al Altomari global head, business development and commercial operations.
BioMS Medical Corp., of Edmonton, Alberta, appointed Mark Krantz director of scientific affairs and Les Ferenczi biostatistician.
Callisto Pharmaceuticals Inc., of New York, added Kenneth Anderson to its scientific advisory board.
Chiron Corp., of Emeryville, Calif., said Andrew Heaton, its vice president and chief medical officer, Chiron blood testing division, was appointed to the federal advisory committee of blood safety and availability.
Constella Health Strategies, of Boston, a unit of Constella Group Inc., hired Junaid Husain as director of marketing and business development.
Cubist Pharmaceuticals Inc., of Lexington, Calif., appointed William Martone executive director, medical affairs.
Dendreon Corp., of Seattle, promoted Grant Pickering to senior vice president of operations.
Devgen NV, of Ghent, Belgium, appointed Pierre Hochuli nonexecutive chairman.
DxS Ltd., of Manchester, UK, appointed Hans Vanhooren European business development manager.
Dynavax Technologies Corp., of Berkeley, Calif., appointed Daniel Levitt vice president and chief medical officer.
Endovasc Inc., of Montgomery, Texas, elected Diane Dottavio to its board.
Evotec OAI AG, of Hamburg, Germany, appointed Bernard Questier chief business officer.
Exelixis Inc., of South San Francisco, added Frank McCormick to its board.
FibroGen Inc., of South San Francisco, appointed Claire Lockey vice president of regulatory affairs.
Genaissance Pharmaceuticals Inc., of New Haven, Conn., named Richard Judson chief scientific officer.
Genome BioSciences Inc., of Temecula, Calif., added Fred Gage to its scientific advisory group.